Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Xilio Therapeutics, Inc. - Common Stock (NQ: XLO )

1.140 -0.150 (-11.63%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 9,348,416
Open 1.290
Bid (Size) 1.120 (10)
Ask (Size) 1.140 (8)
Prev. Close 1.290
Today's Range 1.000 - 1.300
52wk Range 0.5340 - 1.700
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Unusual volume stocks in Friday's session
Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume. 
Via Chartmill
The trading volume of these stocks is deviating from the norm in today's session.
The trading volume of these stocks is deviating from the norm in today's session. 
Via Chartmill

Performance

YTD
+6.54%
+6.54%
1 Month
N/A
N/A
3 Month
+17.25%
+17.25%
6 Month
+23.93%
+23.93%
1 Year
+86.58%
+86.58%

More News

Read More
Keep an eye on the top gainers and losers in Wednesday's session.
Via Chartmill
These stocks are the most active in today's session
Via Chartmill
Nasdaq Edges Higher; CVS Health Shares Jump Following Upbeat Earnings
Via Benzinga
Let's have a look at the top gainers and losers in the middle of the day of today's session.
Via Chartmill
Crude Oil Down Over 2%; Upstart Shares Jump Following Earnings
Via Benzinga
Exposures Fossil Fuels
Traders are paying attention to the gapping stocks in Wednesday's session.
Via Chartmill
Why Is Nano-Cap Cancer-Focused Xilio Therapeutics Stock Trading Over 100% On Wednesday?
Via Benzinga
Dow Dips Over 300 Points; US Inflation Increases More Than Expected
Via Benzinga
Topics Economy Stocks
Exposures Interest Rates US Equities
Wednesday's pre-market session: top gainers and losers
Via Chartmill
Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs
From Xilio Therapeutics, Inc.
Via GlobeNewswire
AbbVie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies
From Xilio Therapeutics, Inc.; AbbVie Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Why FedEx Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Xilio Therapeutics, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Advanced Solid Tumors
From Xilio Therapeutics, Inc.
Via GlobeNewswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.